Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cost of Revenue for 3 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 100.45% to $7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.6 million, a 183.44% increase, with the full-year FY2025 number at $22.6 million, up 183.44% from a year prior.
  • Cost of Revenue was $7.6 million for Q4 2025 at Phathom Pharmaceuticals, up from $6.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $7.6 million in Q4 2025 to a low of $167000.0 in Q4 2023.
  • A 3-year average of $3.4 million and a median of $3.7 million in 2025 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 2184.43% in 2024, then surged 100.45% in 2025.
  • Phathom Pharmaceuticals' Cost of Revenue stood at $167000.0 in 2023, then surged by 2184.43% to $3.8 million in 2024, then soared by 100.45% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Cost of Revenue are $7.6 million (Q4 2025), $6.2 million (Q3 2025), and $5.0 million (Q2 2025).